In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of UCLouvain, in close collaboration with Willem de Vos, professor at UWageningen, discovered the beneficial effects of an intestinal bacteria, Akkermansia muciniphila1, able to moderate the development of obesity and type 2 diabetes, in mice. In 2017, the team discovered (still in the mouse) that the use of a pasteurized form of Akkermansia leads to an even greater protection than the living bacterium regarding various cardiovascular disease risk factors such as insulin resistance, hypercholesterolemia, or the storage of fat in adipose tissue.
Following these discoveries, the UCLouvain team, in collaboration with the Cliniques universitaires Saint-Luc2, developed a clinical study in order to administer the bacteria to humans. For this, it was necessary to develop the capacity to produce the bacterium in large quantity and to make sure that the tests would be without risk for the participants.
The UCLouvain researchers administered Akkermansia to overweight or obese volunteers, all displaying insulin resistance (pre-diabetes type 2) and metabolic syndrome, in other words, having several elevated risk factors for cardiovascular diseases. The volunteers were randomly divided into 3 groups (placebo, live bacteria and pasteurized bacteria) and were asked not to change their dietary habits or their physical activity. Akkermansia was provided as a nutritional supplement.
The primary goal of this UCLouvain study was to demonstrate the feasibility of daily ingesting Akkermansia for 3 months, without risk. Clara Depommier and Amandine Everard, UCLouvain researchers, observed excellent compliance (the supplements were easy to ingest) and tolerance (there were no side effects) in the groups taking live or pasteurized bacteria.
The conclusions are clear: the tests in humans confirm what had already been observed in mice. Ingestion of the (pasteurized) bacterium prevented the deterioration of the health status of the subjects (pre-diabetes, cardiovascular risks). Even better, the researchers observed a decrease in inflammation markers in the liver, a slight decrease in the body weight of the subjects (2.3 kg on average)3 as well as a lowering of cholesterol levels. In contrast, the metabolic parameters (insulin resistance or hypercholesterolemia) in placebo subjects continued to deteriorate over time.
Who does it benefit? According to the WHO, one in three people die every day from cardiovascular disease worldwide. In Western countries, one in two people is overweight and has increased cardiovascular risks. This research of the UCLouvain would limit these risks and therefore potentially have an impact (limit the effects) on half of the population, if properly used.
In conclusion, this pilot study demonstrates the feasibility of administrating (pasteurized) Akkermansia bacteria to humans in the form of a food supplement and reports encouraging results on the effectiveness of the Akkermansia-based dietary supplements to reduce cardio-metabolic risk factors. These results pave the way for a large-scale study, to confirm/elaborate these first results, but also endorse the commercialization of the bacteria as food supplements.
A generic email address has been created for the public who wants more information about Akkermansia bacteria: [email protected]
Learn and see more: A bacteria likely to reduce the cardiovascular risks of 1 in 2 people
The Latest on: Akkermansia
via Google News
The Latest on: Akkermansia
- The Truth About The Zone Dieton August 3, 2022 at 8:23 am
The Zone Diet is a low-calorie, low-carb, high-protein diet that tells you what foods to eat and avoid and how much to eat. But is it just a well-marketed fad?
- Ecological principles at play in gut microbiomeon August 3, 2022 at 4:27 am
The dense, diverse collection of bacteria and other microorganisms that begin colonizing the human gastrointestinal tract from birth—collectively called the gut microbiome—is known to influence ...
- The Impact of One Gut Microbe on Human Immunity is Decipheredon July 28, 2022 at 2:44 am
Now thanks to Xavier and colleagues, we know a lot more about one gut microbe, the bacterium Akkermansia muciniphila. This microbe typically represents around three percent of the gut microbiome, and ...
- In rare feat, researchers decipher how one gut bacterium influences immunityon July 27, 2022 at 11:14 am
From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. But with hundreds of bacterial species populating our ...
- Bacterial bullseye: In rare feat, researchers decipher how one gut bacterium influences immunityon July 27, 2022 at 11:01 am
"That's very rare." Clardy, Xavier, and colleagues focused on Akkermansia muciniphila, a species that accounts for an impressive 3 percent of the gut microbiome. It gets its name from the ...
- Bacterial bullseyeon July 27, 2022 at 8:03 am
“That’s very rare.” Clardy, Xavier, and colleagues focused on Akkermansia muciniphila, a species that accounts for an impressive 3 percent of the gut microbiome. It gets its name from the intestinal ...
- Hopes world’s first appetite-suppressant pill will help thousands lose weight safelyon July 19, 2022 at 9:34 am
We hope to develop D3 as the safest and cheapest weight-loss drug “D3 can not only suppress appetite, but also increase the abundance of the weight-loss bacteria Akkermansia muciniphila ...
- Probiotic containing common gut bacterium could halve cardiovascular disease rateson July 2, 2022 at 5:00 pm
An intestinal bacterium named Akkermansia muciniphila was discovered in 2007 by Patrice Cani, a FNRS-WELBIO researcher, and his team at the Louvain Drug Research Institute of University of Louvain.
- Thanks to a Novel Protein, We Could Bring an End to Obesityon March 3, 2017 at 2:06 am
Since December 2015, Akkermansia-based treatment trials for humans have been ongoing. While the effects are yet to be conclusive, it's clear that the treatment isn't harmful to humans — after ...
via Bing News